Manipal AcuNova, India’s “Best Emerging CRO” Standardizes on Thermo’s Finnigan™ TSQ Quantum Ultra™ Mass Spectrometers
23 Jan 2006Thermo Electron Corporation (NYSE: TMO), the world leader in analytical instruments, announces that Manipal AcuNova, ‘India’s best emerging CRO’ and leading player in biotechnology and clinical research, has standardized on Thermo’s Finnigan™ TSQ Quantum Ultra™ triple quadrupole mass spectrometers.
Manipal AcuNova employs the instruments for routine operation in its high-sensitivity, high-throughput Drug Metabolism and Pharmacokinetics (DMPK) laboratory. The Finnigan TSQ Quantum Ultra mass spectrometers were chosen because of the instruments’ enhanced LC-MS/MS assay sensitivity, providing significant advantages for Manipal AcuNova during its demanding DMPK applications.
Speaking about the standardization, Mr. D. A. Prasanna, Vice Chairman and Managing Director at Manipal AcuNova, commented, “By standardizing on Thermo’s instrument, we are able to take advantage of its tried and tested features to leverage our position as one of the most promising CROs in the market.”
Manipal AcuNova is a joint venture between Manipal Education and Medical Group and AcuNova. It was recently awarded with “India’s best emerging CRO of 2005” award by Proximare Inc., a New Jersey based leading strategic management consulting firm which develops and implements growth strategies for pharmaceutical and biotech companies.
Providing enhanced ion transmission and increased sensitivity, Thermo’s Finnigan TSQ Quantum Ultra series triple quadrupoles are the only commercial triple quadrupoles available today capable of performing Highly Selective Reaction Monitoring (H-SRM). H-SRM significantly increases quantitative specificity by eliminating matrix interferences. Ensuring rapid and accurate sample analysis, the Finnigan TSQ Quantum Ultra is designed for high productivity environments such as environmental, clinical and drug discovery laboratories.